Colhoun HM, Betteridge DJ,
Durrington PN, et al, on behalf of the CARDS Investigators.
Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre randomised
placebo-controlled trial. Lancet. 2004;364:685-696.
Colhoun HM, Betteridge DJ,
Durrington PN, et al, on behalf of the CARDS Investigators.
Rapid emergence of effect of atorvastatin on cardiovascular
outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetologia. 2005;48:2482-2485.
Hanlon JT, Pieper CF, Hajjar
ER, et al. Incidence and predictors of all and preventable
adverse drug reactions in frail elderly persons after
hospital stay. J Gerontol A Biol Sci Med Sci.
2006;61(5):511-515.
Hey-Hadavi JH, Kuntze E, Luo
D, Silverman P, Pittman D, LePetri B. Tolerability of
atorvastatin in a population aged ≥65 years: a retrospective
pooled analysis from fifty randomized clinical trials. Am
J Geriatr Pharmacother. 2006;4:112-122.
Khush KK, Waters DD, Bittner
V, et al. Effect of high-dose atorvastatin on
hospitalizations for heart failure: subgroup analysis of the
Treating to New Targets (TNT) study. Circulation.
2007;115(5):576-583.
Koren MJ, Hunninghake DB, on
behalf of the ALLIANCE Investigators. Clinical outcomes in
managed-care patients with coronary heart disease treated
aggressively in lipid-lowering disease management clinics:
The ALLIANCE study.
J Am Coll Cardiol. 2004;44(9):1772-1779.
LaRosa JC, Grundy SM, Waters
DD, et al, for the Treating to New Targets (TNT)
Investigators. Intensive lipid lowering with atorvastatin in
patients with stable coronary disease. N Engl J Med.
2005;352:1425-1435. [baseline paper]
Newman CB, Palmer G,
Silbershatz H, Szarek M. Safety of atorvastatin derived from
analysis of 44 completed trials in 9,416 patients. Am J
Cardiol. 2003;92:670-676.
Newman C, Tsai J, Szarek M,
Luo D, Gibson E. Comparative safety of atorvastatin 80 mg
versus 10 mg derived from analysis of 49 completed trials in
14,236 patients. Am J Cardiol. 2006;97:61-67.
Sever PS, Dahlöf B, Poulter
NR, et al, for the ASCOT Investigators. Prevention of
coronary and stroke events with atorvastatin in hypertensive
patients who have average or lower-than-average cholesterol
concentrations, in the Anglo-Scandinavian Cardiac Outcomes
Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre
randomised controlled trial. Lancet.
2003;361:1149-1158.
Smith SC Jr, Allen J, Blair
SN, et al. AHA/ACC guidelines for secondary prevention for
patients with coronary and other atherosclerotic vascular
disease: 2006 update: endorsed by the National Heart, Lung,
and Blood Institute. J Am Coll Cardiol.
2006;47:2130-2139.